Literature DB >> 15047516

Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Toshimi Kimura1, Keisuke Sunakawa, Nobuo Matsuura, Hiroaki Kubo, Shigehiko Shimada, Kazuo Yago.   

Abstract

Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n = 41), vancomycin (n = 19), or panipenem (n = 23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CL(arbekacin) = 0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CL(arbekacin) = 0.0367 x BW/serum creatinine level for PCAs of > or = 33 weeks, V(arbekacin) = 0.54 liters/kg, CL(vancomycin) = 0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CL(vancomycin) = 0.0323 x BW/serum creatinine level for PCAs of > or = 34 weeks, V(vancomycin) = 0.66 liters/kg, CL(panipenem) = 0.0832 for PCAs of <33 weeks and CL(panipenem) = 0.179 x BW for PCAs of > or = 33 weeks, and V(panipenem) = 0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of > or = 33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047516      PMCID: PMC375245          DOI: 10.1128/AAC.48.4.1159-1167.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age.

Authors:  N Kacet; M Roussel-Delvallez; C Gremillet; J P Dubos; L Storme; P Lequien
Journal:  Pediatr Infect Dis J       Date:  1992-05       Impact factor: 2.129

2.  Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.

Authors:  A H Burstein; L E Wyble; P Gal; P R Diaz; J L Ransom; R Q Carlos; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Pharmacokinetics of amikacin in neonates.

Authors:  E M Padovani; C Pistolesi; V Fanos; A Messori; N Martini
Journal:  Dev Pharmacol Ther       Date:  1993

4.  Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin.

Authors:  J N van den Anker; W C Hop; R C Schoemaker; B J van der Heijden; H J Neijens; R de Groot
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

5.  Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.

Authors:  J N van den Anker; R C Schoemaker; W C Hop; B J van der Heijden; A Weber; P J Sauer; H J Neijens; R de Groot
Journal:  Clin Pharmacol Ther       Date:  1995-12       Impact factor: 6.875

6.  Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks.

Authors:  J J Huisman-de Boer; J N van den Anker; M Vogel; W H Goessens; R C Schoemaker; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Population pharmacokinetics of ceftizoxime in premature newborns.

Authors:  P Karna; C Lee; A Kumar; J Dyke; W M Gooch
Journal:  Dev Pharmacol Ther       Date:  1993

8.  Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts.

Authors:  Y Deguchi; R Koshida; E Nakashima; R Watanabe; N Taniguchi; F Ichimura; A Tsuji
Journal:  J Pharm Sci       Date:  1988-08       Impact factor: 3.534

Review 9.  The pharmacokinetics of meropenem.

Authors:  G L Drusano; M Hutchison
Journal:  Scand J Infect Dis Suppl       Date:  1995

10.  [Pharmacokinetics of ceftazidime in newborn infants].

Authors:  R Rule; N J Martiarena; M Rubio; A Magadan
Journal:  Medicina (B Aires)       Date:  1993       Impact factor: 0.653

View more
  27 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.

Authors:  María-Remedios Marqués-Miñana; Anas Saadeddin; José-Esteban Peris
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 3.  Population clinical pharmacology of children: modelling covariate effects.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

4.  Population pharmacokinetic and pharmacodynamic modeling of norvancomycin.

Authors:  J Zhang; Y Zhang; Y Shi; J Rui; J Yu; G Cao; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

5.  Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.

Authors:  Julianne Kim; Sandra A N Walker; Dolores C Iaboni; Scott E Walker; Marion Elligsen; Michael S Dunn; Vanessa G Allen; Andrew Simor
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Authors:  Yoke-Lin Lo; Johan G C van Hasselt; Siow-Chin Heng; Chin-Theam Lim; Toong-Chow Lee; Bruce G Charles
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 7.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Yusuke Tanigawara; Reiko Sato; Kunihiko Morita; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

9.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

Authors:  Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

10.  Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study.

Authors:  Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.